Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis

@article{Campbell2017MetforminRA,
  title={Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis},
  author={Jared M. Campbell and Susan M. Bellman and Matthew Stephenson and Karolina Lisy},
  journal={Ageing Research Reviews},
  year={2017},
  volume={40},
  pages={31-44}
}
This systematic review investigated whether the insulin sensitiser metformin has a geroprotective effect in humans. Pubmed and Embase were searched along with databases of unpublished studies. Eligible research investigated the effect of metformin on all-cause mortality or diseases of ageing relative to non-diabetic populations or diabetics receiving other therapies with adjustment for disease control achieved. Overall, 260 full-texts were reviewed and 53 met the inclusion criteria. Diabetics… Expand
Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
TLDR
This finding, at least in part, shows no evidence for benefits of metformin in combination in terms of all-cause/cardiovascular mortality and cardiovascular events for T2DM, however, the conclusion shall be explained cautiously considering the limitations from UK Prospective Diabetes Study. Expand
Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis
TLDR
Metformin use is connected with significantly less risks of all-cause mortality and cardiovascular events in patients with T2DM and mild/moderate CKD, however, RCTs with large sample sizes are warranted to assess whether these key benefits extend to later stages of CKD by dose adjustment. Expand
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis
TLDR
Metformin reduces cardiovascular mortality, all-cause mortality and CV events in CAD patients and is superior to sulphonylurea in effects on lowering the incidence of CV events and in results on patients who don’t use medication. Expand
Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis
TLDR
The use of metformin by individuals without diabetes for the prevention of dementia is not supported by the available evidence, and it should continue to be used as a first line therapy for diabetes in patients at risk of developing dementia or Alzheimer’s disease. Expand
A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
TLDR
Although the presence of CKD attenuated the mortality benefit, metformin may be a safer alternative to sulfonylureas in patients with CKD, which is associated with higher risk for all-cause mortality, major hypoglycemic episodes, and cardiovascular events compared with met formin. Expand
Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases
TLDR
B12 monitoring for MET-treated individuals should be implemented, as a significant overall reduction in both serum total B12 and holo-TC-II levels according with MET-treatment is indicated. Expand
Association of Metformin Use With Age-Related Macular Degeneration: A Case-Control Study.
TLDR
It is suggested that metformin may be useful as a preventive therapy for AMD and provides the basis for potential prospective clinical trials. Expand
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
TLDR
Some arguments supporting the initiation of metformin in patients with newly diagnosed T2DM, especially those without cardiovascular risk factors or without established cardiovascular disease or advanced kidney insufficiency at the time of new guidelines favoring new drugs with pleotropic effects complimentary to glucose control are presented. Expand
Mechanisms of action of metformin with special reference to cardiovascular protection
TLDR
Multiple potential mechanisms support the concept of cardiovascular protection with metformin beyond those provided by reduced blood glucose, including weight loss, improvements in haemostatic function, reduced inflammation, and oxidative stress, and inhibition of key steps in the process of atherosclerosis. Expand
Understanding the cardiovascular risk with non-insulin antidiabetic drugs
TLDR
The cardiovascular safety of DPP-4 inhibitors has been demonstrated, without however significant morbidity and mortality benefits, and SGLT-2 inhibitors and GLP-1 analogues offer significant cardiovascular benefits and are recommended for patients with overt cardiovascular disease. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis
TLDR
The findings suggest that the use of metformin is in favor of the prognosis of patients with kidney cancers, and further investigations are needed to evaluate the prognostic value of metforms on kidney cancer patients. Expand
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
TLDR
A protective effect for liver cancer was found in diabetic metformin users, however, more randomized clinical evidence is still needed to verify the results. Expand
Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis
TLDR
Metformin prolongs the OS of diabetic CRC patients, but it does not affect the CRC-specific survival and may be a good choice in treating CRC patients with diabetes mellitus in clinical settings. Expand
Effect of Metformin-Containing Antidiabetic Regimens on All-cause Mortality in Veterans With Type 2 Diabetes Mellitus
TLDR
Treatment of T2DM with regimens containing metformin alone or in combination with other hypoglycemic agents was associated with reduced all-cause mortality compared with regimen without metformIn. Expand
The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
  • E. Andreadis, P. Katsanou, +4 authors E. Diamantopoulos
  • Medicine
  • Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 2009
TLDR
Metformin reduces the occurrence of T (2)DM in overweight and obese non-diabetic adults and decreases the rate of MetS by improving the CVD risk factor profile. Expand
14-Year Risk of All-Cause Mortality According to Hypoglycaemic Drug Exposure in a General Population
TLDR
The results support the conclusion that until more evidence is provided from randomized trials, a prudent approach should be to restrain use of insulin to situations in which combinations of non-insulin agents have failed to appropriately achieve glycemic control, as it is recommended in the current guidelines for the management of type 2 diabetes. Expand
Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
TLDR
Metformin showed lower risk than insulin for CVD and all-cause mortality and slightly lower risk for all- cause mortality compared with other OHA, in these 51 675 patients followed for 4 years, and the benefits of metformin use clearly outbalance the risk of severe side effects. Expand
Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis
TLDR
This study showed that metformin use was significantly associated with a decreased incidence of EC in diabetes and a favorable survival outcome of EC patients. Expand
Long-term metformin usage and cognitive function among older adults with diabetes.
TLDR
Among individuals with diabetes, long-term treatment with metformin may reduce the risk of cognitive decline and dementia and suggests that insulin sensitizers may protect against cognitive decline in diabetic and pre-diabetic individuals. Expand
Metformin does not alter the risk of lung cancer: a case-control analysis.
TLDR
Metformin did not decrease the risk of lung cancer and the contribution of potential confounders including tuberculosis, chronic obstructive pulmonary disease, diabetes mellitus, and co-morbid conditions to diabetes was evaluated in univariate models. Expand
...
1
2
3
4
5
...